Background: Stereotactic ablative radiotherapy (SABR) is emerging as a potential local treatment option for oligometastatic RCC. This study aims to evaluate the efficacy of SABR in patients with oligorecurrent RCC. Methods: A total of 50 patients with histologically confirmed RCC underwent SABR for oligorecurrence between 2006 and 2022. Eligible patients had up to five extracranial metastases and were systemic treatment-naïve at the time of irradiation. The primary endpoints of the analysis were overall survival (OS), local control (LC), distant metastasis–free survival (DMFS), and time to systemic therapy initiation. Results: The median OS was not reached, with 1- and 3-year OS rates of 93.8% and 77.5%, respectively. LC rates at one and three years were 95.8% and 86.5%, respectively. The median time to systemic therapy initiation was 63.8 months, and the median DMFS was 17.9 months, with one- and three-year rates of 63.4% and 36.6%, respectively. Multiple metastases were a negative predictive factor for DMFS (HR 2.39,p= 0.023), whereas lung metastases were associated with a more favorable outcome (HR 0.38,p= 0.011). Conclusions: SABR offers a valuable treatment option for oligometastatic RCC, demonstrating significant potential for achieving long-term disease control and delaying the need for systemic therapy.
背景：立体定向消融放疗（SABR）正逐渐成为寡转移性肾细胞癌（RCC）的潜在局部治疗选择。本研究旨在评估SABR在寡复发RCC患者中的疗效。方法：2006年至2022年间，共有50例经组织学确诊的RCC患者因寡复发接受SABR治疗。符合条件者最多存在五处颅外转移灶，且在放疗时未接受过全身治疗。分析的主要终点包括总生存期（OS）、局部控制率（LC）、无远处转移生存期（DMFS）以及至开始全身治疗的时间。结果：中位OS未达到，1年和3年OS率分别为93.8%和77.5%。1年及3年LC率分别为95.8%和86.5%。至开始全身治疗的中位时间为63.8个月，中位DMFS为17.9个月，1年及3年DMFS率分别为63.4%和36.6%。多发性转移是DMFS的负面预测因素（HR 2.39，p=0.023），而肺转移则与更良好的预后相关（HR 0.38，p=0.011）。结论：SABR为寡转移性RCC提供了有价值的治疗选择，在实现长期疾病控制和延迟全身治疗需求方面展现出显著潜力。
肿瘤(癌症)患者之家